Mike Youle - Concepedia

Author

Mike Youle

Also Known As

Alan Winston, Chris Wood, Jan Gerstoft, Juan Manuel Tiraboschi, M Youle, MIKE YOULE, Margaret Johnson, Mike S Youle, Mike Youle

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

University College London The Royal Free Hospital Chelsea and Westminster Hospital Imperial College London Mortimer Market Centre

About

Mike Youle is an author at University College London specializing in hiv, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	1.5K
2	Public Health	3	3	160
3	Health Sciences	2	2	76
4	Anesthesia	1	1	84
5	Cell Biology	1	1	50

Mike Youle

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 Gerd Fätkenheuer, Anton Pozniak, Margaret Johnson, Nature Medicine Treatment And PreventionMedicineImmunologyAntiviral Drug DevelopmentAntiviral Therapy	2005	490
Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir Mike Westby, Marilyn Lewis, Jeannette M. Whitcomb, Journal of Virology Ccr5 Antagonist MaravirocCcr5 TropicHuman RetrovirusPretreatment Cxcr4-using ReservoirImmunology	2006	330
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy Helen Devereux, Mike Youle, Margaret Johnson, AIDS	1999	285
Late presenters in the era of highly active antiretroviral therapy Caroline Sabin, Colette Smith, Helen Gumley, AIDS	2004	213
Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Trial Ulrik Bak Dragsted, Jan Gerstoft, Court Pedersen, The Journal of Infectious Diseases Assigned TreatmentAdverse EventsIndinavir/ritonavir Versus Saquinavir/ritonavirMaxcmin1 TrialHuman Retrovirus	2003	118
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment Ward Schrooten, Robert Colebunders, Mike Youle, AIDS	2001	117
Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy Fiona Lampe, José M. Gatell, Schlomo Staszewski, Archives of Internal Medicine	2006	91
Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers Caroline Sabin, Colette Smith, Mike Youle, AIDS	2005	88
Systemic acetyl-l-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma Andrew Hart, Mikael Wiberg, Mike Youle, Experimental Brain Research Peripheral AxotomyPeripheral NervesPeripheral Nerve InjuryNeurophysiologyNeuroanatomy	2002	84
The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy Colette Smith, Caroline Sabin, Fiona Lampe, AIDS	2003	80

Page 1